|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Together, our study represents a first approach to the separation of essential molecular consequences from noise generated by the EWS-FLI1 gene rearrangement in ESFT.
|
17163154 |
2006 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytopathological findings of primary pulmonary Ewing family of tumors with EWSR1 translocation: A case report.
|
27766786 |
2016 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
EWS/FLI1 inhibition results in a novel adaptive response and suggests that targeting the IL6/STAT3 signaling pathway may increase the efficacy of ESFT therapies.
|
25092916 |
2014 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ewing sarcoma family of tumors research has benefited from new target discovery and enhanced biologic understanding of the EWS-FLI1 fusion protein.
|
15659957 |
2005 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that ET-743 reverses a gene signature of induced downstream targets of EWS-FLI1 in two different ESFT cell lines (P = .001).
|
21403840 |
2011 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ewing sarcoma/peripheral primitive neuroectodermal tumor (EWS/pPNET) and other tumors with EWS gene rearrangements encompass a malignant and intermediate neoplasm with a broad anatomic distribution and a wide age range but a predilection for soft tissue in children, adolescents, and young adults.
|
22420726 |
2012 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ewing sarcoma family of tumors (ESFTs) are characterized by the t(11;22)(q24;q12) translocation that generates the Ewing sarcoma breakpoint region 1 and Friend leukemia virus integration 1 (EWS-FLI1) fusion transcription factor responsible for the highly malignant phenotype of this tumor.
|
21653923 |
2011 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is not a single condition, but a group of morphologically and clinically closely related disorders with similar molecular biology -- expression of tumor-specific chimeric oncoproteins through balanced chromosomal translocations involving the EWS gene -- often referred to as the Ewing family of tumors.
|
15877528 |
2005 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Rearrangements of the EWS gene with ETS transcription factor genes as a result of chromosomal translocation and high expression levels of CD99MIC2 characterize the Ewing family of tumors (EFT).
|
10565682 |
1999 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The genetic hallmark of ESFT is the presence of the t(11;22)(q24;q12), which creates the EWS/FLI1 fusion gene and results in the expression of a chimeric protein.
|
10888417 |
2000 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High CD99 expression levels and rearrangements of the EWS gene with ETS transcription factor genes characterize the Ewing's sarcoma family of tumors (ESFT).
|
16314831 |
2006 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The Ewing sarcoma family of tumors (ESFT) is defined by cell surface expression of CD99 and a translocation involving EWS and an ETS partner.
|
23760780 |
2013 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
EWS-erg and EWS-Fli-1, which are involved in greater than 95% of Ewing family of tumors, were shown to function as transcriptional activators.
|
9178886 |
1997 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to EWS/FLI1 gene fusion, copy number changes are known to be significant for the underlying neoplastic development of ESFT and for patient outcome.
|
19144156 |
2009 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fluorescence in situ hybridization (FISH) indicated a rearrangement of the EWS region on chromosome 22, which is highly specific for Ewing's sarcoma and PNET, which are referred to as the Ewing's sarcoma family of tumors (EFT).
|
17610475 |
2007 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fusions of ETS with the EWSR1 partner gene define many members of the Ewing family of tumors, including primitive neuroectodermal tumor (PNET).
|
31831298 |
2020 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aims of this study were (1) to present the diverse clinicopathological and molecular profile of EFTs in our settings, (2) to identify a pragmatic approach for diagnosing EFTs, especially for application of ancillary techniques, namely RT-PCR for specific transcripts (EWS-FLI1, EWS-ERG) and FISH for EWSR1 gene rearrangement, in certain cases and (3) to show the utility of tissue microarray in establishing a new FISH test.
|
24293381 |
2014 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ewing's sarcoma family of tumors (EFT) is characterized by the presence of chromosomal translocations leading to the expression of oncogenic transcription factors such as, in the majority of cases, EWS/FLI1.
|
22323082 |
2012 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
This report may provide an opportunity for further evaluation of the EWS-FLI1 type 1 fusion gene and detection of prognostic significance in periosteal ESFT.
|
17762498 |
2007 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since a relation was reported between PDGF-C and EWS/FLI1, we sought to characterize the PDGF signaling pathway in ESFT.
|
12700668 |
2003 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The translocation t(11;22)(q24;q12) is the most common and leads to the formation of the EWS-FLI1 fusion protein, which contributes to ESFT pathogenesis by modulating the expression of target genes.
|
16096383 |
2005 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The EWS/FLI1 translocations were detected in 7/8 (87.5%) ESFTs cases, whereas non of 8 cPNET cases were detected with this translocation.
|
21267687 |
2011 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diagnosis of EFTs is confirmed by molecular diagnostic testing showing the presence of established rearrangements of the EWS gene.
|
19411158 |
2009 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively monitored tumor contamination in stem cell harvests from patients with Ewing family of tumors (EFT) all harboring the specific translocation EWS-FLI-1 that characterize these tumors.
|
15049010 |
2004 |
|
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of specific EWS-FLI1 or EWS-ERG transcripts in peripheral blood (PB) samples of patients being treated for ET was prospectively evaluated, and these data were correlated to their clinical status.
|
9836070 |
1998 |